Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy, in Subjects With Tumors With Oncogene...
Non-small Cell Lung CancerNon-Small Cell Lung Adenocarcinoma9 moreBBI-355 is an orally available, potent, and selective checkpoint kinase 1 (or CHK1) small molecule inhibitor in development as an ecDNA (extrachromosomal DNA) directed therapy (ecDTx). This is a first-in-human, open-label, non-randomized, 3-part, Phase 1/2 study to determine the safety profile and identify the maximum tolerated dose and recommended Phase 2 dose of BBI-355 administered as a single agent or in combination with select therapies.
HRYZ-T101 TCR-T Cell for HPV-18 Positive Advanced Solid Tumor
Cervical CancerHead and Neck Squamous Cell Carcinoma5 moreA single center, open, single arm dose escalation phase I study to evaluate the safety, tolerability, and efficacy of HRYZ-T101 TCR-T cell for HPV18 positive advanced solid tumor. The study will investigate DLT of HRYZ-T101 TCR-T cell injection.
Pilot Study of Imatinib Cetuximab Combo for H & N Cancer
Head and Neck CancerSquamous Cell Carcinoma of Head and NeckThe goal of this clinical trial is to find if levels of a protein called AXL in tumor cells relate to how tumors respond to cetuximab (CTX) combined with imatinib in participants with head and neck cancer. This interventional study will occur in the time between diagnosis of your cancer and surgery to remove your tumor or radiation or chemoradiation treatment of your primary cancer. Participants will undergo a research blood draw and a research biopsy as part of the screening process, and will be in this research study for approximately 13 to 16 months.
A Study of Decreasing Radiation Therapy and Chemotherapy in People With Head and Neck Cancer
Head and Neck CancerHead and Neck Carcinoma2 moreThe purpose of this study is to test the treatment approach of de-escalated radiation and chemotherapy followed by a planned neck dissection surgery in people with head and neck cancer. The study will look at how effective the treatment approach is against participants' cancer.
Tislelizumab Combined With Chemotherapy Followed by Surgery Versus Up-front Surgery in Resectable...
Head and Neck Squamous Cell CarcinomasA prospective, randomized, open-label, multicenter Phase 3 trial designed to compare the safety and efficacy of Tislelizumab combined with chemotherapy followed by surgery versus up-front surgery in resectable head and neck squamous cell carcinoma.
Neoadjuvant Chemotherapytreatment of Locally Advanced Head and Neck Squamous Cell Carcinoma
Head and Neck Squamous Cell CarcinomaNeoadjuvant ChemotherapyThe objective of research is to evaluate the efficacy and safety of treprizumab injection combined with AP regimen in the treatment of resectable locally advanced head and neck squamous cell carcinoma.122 patients were randomly divided into two groups: the test group (treprizumab injection combined with AP protocol) and the control group (TP protocol); The patients in both groups were treated with three cycles of induction therapy. After the induction therapy, the patients were evaluated and followed up with surgery.
Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous...
Head and Neck Squamous Cell CarcinomaHead and Neck CancerThis study is designed to evaluate the efficacy and safety of tislelizumab and tislelizumab in combination with investigational agent(s) in first-line recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors
MelanomaNon Small Cell Lung Cancer15 moreAI-061 is a co-formulation drug product (DP) consisting of 1:1 ratio mix of AI-025, an anti-PD-1 antibody, and ONC-392, an anti-CTLA-4 antibody. This is a dose escalation study to identify the maximum toxicity dose (MTD) or the recommended phase 2 dose (RP2D).
Pembrolizumab and Lenvatinib After Definitive Chemoradiation of Locally Advanced HNSCC
Head and Neck Squamous Cell CarcinomaOpen-label, single-arm, prospective multicenter phase II clinical trial to determine the efficacy and safety combined pembrolizumab and lenvatinib as maintenance therapy after definitive radiochemotherapy of locally advanced head and neck squamous cell carcinoma (HNSCC).
A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the...
Advanced Head and Neck Squamous Cell CarcinomaAdvanced Breast Cancer1 moreThis Phase 1b/2a study will assess the efficacy, safety, and pharmacodynamics of CyPep-1 when administered directly into measurable tumor lesions in combination with the anti-PD-1 antibody pembrolizumab. Additionally, the study will assess anti-tumor effects of CyPep-1 on injected lesions and non-injected target lesions identified at baseline, as well as local and systemic immunological effects of CyPep-1 in combination with pembrolizumab.